(Q24244575)

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

Acute renal failure resulting from intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Assessment of current diagnostic criteria for Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Plasma exchange in Guillain-Barré syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Complications of intravenous gammaglobulin in neuromuscular and other diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Anaphylaxis with intravenous gammaglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Severe Guillain-Barré syndrome in childhood treated with human immune globulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Controlled trial prednisolone in acute polyneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Eczematous reactions to human immune globulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Aseptic meningitis associated with high dose intravenous immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Epidemiological study of Guillain-Barré syndrome in south east England

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Indicators of rapid clinical recovery in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Treatment of Guillain-Barré syndrome with high-dose gammaglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021

Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB3

7 January 2021